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It is estimated that the number of older women living with breast cancer will quadruple by 2040 [1]. Despite this,
there is a lack of strong evidence and guidelines to support management decisions for this population.
This article has evolved from a conference session on this subject, held at the 2020 UK Interdisciplinary Breast
Cancer Symposium (UKIBCS; West Midlands, UK, 27–28 January 2020) [2]. The UKIBCS is a biennial meeting
for all those with an active interest in breast cancer research and treatment, hosted by the charity Breast Cancer
Now (London, UK), in collaboration with eight other breast cancer focused specialist societies.
In this editorial, we discuss key issues in the management of breast cancer in older women, which include both
tumor and patient factors. We also review current national initiatives to tackle these issues and summarize ongoing
work in this field.
Key perspectives
Tumor factors
Emerging data suggest that the biology of breast cancer in older women is different to that in younger women,
although overall research work is still lacking in this area [3].
The Nottingham group describes possibly the largest consecutive series of older women with primary breast
cancer, with both clinical follow-up data and tumor samples available, documented in the literature. Between 1973
and 2010, 1758 women ≥70 years of age with early stage (clinically ≤5 cm) breast cancer without evidence of
metastases at diagnosis presented to the unit.
Work in this cohort has shown there are differences in survival outcome based on the degree of ER positivity. In a
subset of 1085 patients, those with tumors with ER H-score of ≥250 (out of 300, high ER expression) were found to
have equivalent breast-cancer-specific-survival (BCSS) regardless of primary surgery or primary endocrine therapy
(PET), whereas for patients with tumors with an H-score <250, surgery produced better BCSS (p < 0.001) [4].
Another example is in those patients with HER2-positive tumors. A comparison of 130 younger (<70 years)
patients with 43 older patients identified as having HER2-positive tumors found no difference in BCSS, despite
minimal use of chemotherapy in the older age group, compared with frequent use in the younger group [5]. These
results were replicated in patients with triple negative breast cancer [6]. This suggests that, overall, older women
express a less aggressive phenotype of breast cancer compared with their younger counterparts.
The Nottingham group has gone on to assess a panel of 25 biomarkers in 575 older women undergoing surgery [3].
Cluster analysis demonstrated a novel subtype – low ER luminal (with low ER expression but high expression of
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luminal cytokeratins), previously not seen in younger women. Its identification may explain differences in clinical
outcome among older women and needs future investigations.
Patient factors
Apart from biological differences in the tumor, the older population has unique personal needs, which should be
considered in treatment discussions. Comprehensive geriatric assessment (CGA) is a process used by healthcare
professionals to assess an older person’s physical health and function, mental health and social circumstances. Geri-
atric assessment is recommended by the International Society of Geriatric Oncology (Chaˆtelaine, Switzerland) [7]
but there is no consensus on how it should be implemented or the results interpreted.
Alongside the work described above, the Nottingham group has an ongoing multicenter international prospective
study exploring the potential value of CGA in primary breast cancer patients. A cancer-specific validated CGA
tool [8], as well as measures of quality of life (QoL) are used within 6 weeks of diagnosis and again at 6 months.
Preliminary results show that increasing age, comorbidity, number of medications and slower ‘timed-up-and-go’
score are associated with higher likelihood of receipt of PET over surgery [9].
When exploring treatment decision making with patients, they felt breast cancer treatment was a ‘trade off ’
between risks and benefits of treatment. Furthermore, older women may value QoL and retention of functional
independence more highly than extending the length of life [8,10].
Current national initiatives
Bridging the Age Gap study
The Age Gap study is a multicenter prospective cohort study aiming to optimize the management of older (>70
years) women with breast cancer [11]. This is an extremely important piece of research due to the difficulty of
randomization in this population, resulting in a paucity of randomized controlled trial data. The Age Gap study is
collecting observational real-world data but then using propensity score matching to adjust for treatment allocation
bias rather than randomization. The key question for the Age Gap study was to determine which subgroup of older
women could be safely offered nonstandard care (i.e., PET for primary treatment and omission of chemotherapy
as adjuvant treatment) based on their health, fitness, frailty and tumor characteristics. A key element of the study
was to collect detailed QoL data on all patients in light of the importance of this to women in this age group.
The study is now complete and data analysis is ongoing. The study recruited over 3400 women over the age of
70 years from 57 centers in England and Wales. Preliminary results discussed here were presented at the UKIBCS
and are yet to be published [2].
A comparison of 672 patients (matched for age, frailty and comorbidity) receiving either PET or surgery showed
no difference in BCSS regardless of treatment. After treatment, patients in both groups saw an initial decrease in
QoL from baseline; however, this recovered for patients receiving PET, but not for patients undergoing surgery by
the 2-year mark. This suggests that there is a group of older women who will have no oncological benefit from
surgery and in fact, surgery may be detrimental to their QoL.
The second phase of the study involved the development of a predictive tool to tailor treatment options according
to breast cancer stage and biology and their age, fitness and frailty. A Decision Support Instrument (DESI) was
developed to assist older women in making informed decisions about their preferred treatment [11,12]. A multicenter
cluster randomized trial was then nested within the main Age Gap observational study in 46 of the 57 centers.
These 46 centers were randomized to continue with normal decision-making practice or to have training and the
use of the online DESI. The trial has now completed recruitment and randomized 670 patients to the intervention
(use of the DESI) and 669 to standard care. Preliminary results show early trends toward improved QoL and
identical BCSS in patients who use the DESI, compared with those treated by standard care. The online tool is
now freely available to use [12].
A view on dementia
The National Audit of Breast Cancer in Older Patients is part of an effort to evaluate the quality of cancer care
provided to older (>70 years) women with breast cancer in England and Wales [13]. At the time of publication of
the third annual report in 2019 [13], 147,162 older women diagnosed with breast cancer between 2014 and 2017
had been recruited from 130 centers.
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In the 2017 report, a series of case vignettes were used to gain perspective on patient factors that influence clinical
treatment decisions. The results highlighted inconsistencies in primary treatment preferences of women with breast
cancer and complex multimorbidities such as cognitive impairment and dementia [14].
Fewer women with dementia present with breast cancer at an early stage. In a large (n = 31,935) retrospective
cohort study, Raji et al. [15] found that 28% of patients with breast cancer and dementia were diagnosed with stage I
disease, compared with 50.7% of patients without dementia. Furthermore, it is reported that women with dementia
are up to 40% less likely to have surgery [16] compared with women without dementia. The reasons for this are
complex and multifactorial. For example, patients with dementia are more likely to have competing comorbidities
which may affect their suitability for general anesthesia [17]. Cohort studies have demonstrated a higher rate of
postoperative complications in patients with dementia and breast cancer [18], as well as long-term cognitive effects
and compliance issues for adjuvant therapy [19], but studies of this kind are few. At last, the impact of dementia and
breast cancer on a patient’s life expectancy remains poorly understood.
Given the increasing global burden of dementia [20], it is proposed that the approach to a patient with dementia
should be as any other comorbidity – recognition, optimization and management that involves shared decision
making.
Conclusion
Both tumor and patient factors are different in the older compared with younger woman with breast cancer. The
future of treatment for older women with primary breast cancer should aim to utilize tumor and geriatric factors to
deliver personalized cancer care, including in patients with dementia. This could be supported using tumor-based
prognostic and predictive tools, geriatric assessment and patient decision-making tools. Research and audits in this
area provide important insights and should continue.
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